Susquehanna analyst Mehdi Hosseini lowered the firm’s price target on Viavi to $14 from $16 and keeps a Positive rating on the shares. The analyst updated estimates following its negative pre-release and said the weakness has appeared to spread to the lab/production side of the business, though field test demand continues to stabilize.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VIAV:
